Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens

Zimmermann, Jana; Saalbach, Isolde; Jahn, Doreen; Giersberg, Martin; Haehnel, Sigrun; Wedel, Julia von; Macek, Jeanette; Zoufal, Karen; Glünder, G; Falkenburg, Dieter; Kipriyanov, Sergey M.

doi:10.1186/1472-6750-9-79

Cited by 56 publications

(39 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result, scFvs were generated, in which the two variable regions, VH and VL, are artificially linked by a flexible polypeptide (Fig. 1) [27,28]. This and similar approaches may still be considered as highly convenient once the negative European public perception on biofarming eases its halt in the development of local companies specialized in antibody production.…”

Section: Antibody Fragmentsmentioning

confidence: 99%

Manufacturing antibodies in the plant cell

Orzáez

Granell

Blázquez

2009

Biotechnology Journal

View full text Add to dashboard Cite

International audiencePlants have long been considered advantageous platforms for large-scale production of antibodies due to their low cost, scalability, and the low chances of pathogen contamination. Much effort has therefore been devoted to efficiently produce mAbs (from nanobodies to secretory antibodies) in plant cells. Several technical difficulties have been encountered and are being coped with. Improvements in production levels have been achieved by manipulation of gene expression and, more efficiently, of cell targeting and protein folding and assembly. Differences in mAb glycosylation patterns between animal and plant cells are being successfully addressed by the elimination and introduction of the appropriate enzyme activities in plant cells. Another relevant battlefield is the dichotomy between production capacity and speed. Classically, stably transformed plant lines have been proposed for large scale mAb production, whereas the use of transient expression systems has always provided production speed at the cost of scalability. However, recent advances in transient expression techniques have brought impressive yield improvements, turning speed and scalability highly compatible assets. In the era of personalized medicines, the combination of yield and speed, and the advances in glyco-engineering have made the plant cell a serious contender in the field of recombinant antibody production

show abstract

Section: Antibody Fragmentsmentioning

confidence: 99%

Manufacturing antibodies in the plant cell

Orzáez

Granell

Blázquez

2009

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…When chickens were forced fed with pea seeds bearing anti-Eimeria ScFv, they were protected from subsequent coccidiosis, while purified antibodies (produced from tobacco leaves) failed to provide similar protection (Zimmermann et al, 2009).…”

Section: In Seed Antibody Expressionmentioning

confidence: 99%

“…In addition to the merits of in planta expression, in seed expression enables oral delivery, long-term storage, and ease of handling and transport without cold chain maintenance (Floss et al, 2007, Khan et al, 2012. Seeds can be used directly for passive mucosal immunization, which is particularly advantageous for animal diseases (Floss et al, 2007, Zimmermann et al, 2009, and also for human application. Alternatively, for parenteral application, the high protein concentration in desiccated seeds facilitates the downstream processing.…”

Section: In Seed Antibody Expressionmentioning

confidence: 99%

“…It is reasoned that the seed-specific promoters are usually active during the seed filling stage (development and maturity), while the CaMV P35S ceases expression after the initial stages, explaining the lower accumulation (Chen et al, 1986, Petruccelli et al, 2006. Besides the b-phaseolin promoter (De Jaeger et al, 2002, De Wilde et al, 2013, several other seed-specific promoters, like USP (unknown seed promoter) (Zimmermann et al, 2009), glutelin-1 (gt-1) promoter (Ramessar et al, 2008), legumin A promoter , and maize ubiquitin promoter (Christensen and Quail, 1996), have been evaluated for the expression of antibodies and other therapeutic proteins in plants ( Khan et al, 2012).…”

Section: In Seed Antibody Expressionmentioning

confidence: 99%

See 1 more Smart Citation

Role of plant expression systems in antibody production for passive immunization

Virdi¹,

Depicker²

2013

Int. J. Dev. Biol.

View full text Add to dashboard Cite

Passive immunization is a method to achieve immediate protection against infectious agents by administering pathogen-specific antibodies. It has proven to be lifesaving for many acute infections, and it is now also used for cancer treatment. Passive immunization therapies, however, are extremely expensive because they require large amounts of specific antibodies that are produced predominantly in mammalian expression systems. The cost for manufacturing plant-made antibodies is estimated to be comparatively low since plant production systems require relatively less capital investments. In addition, they are not prone to mammalian pathogens, which also eases downstream processing along with making it a safe expression system. Moreover, some of the recent developments in transient expression have enabled rapid, cGMP (current Good Manufacturing Practices) compliant manufacturing of antibodies. Whether lower production costs will be reflected in a lower market price for purified antibodies will be known when more plant-produced antibodies come to the market. Promisingly, the current molecular techniques in the field of in planta expression have enabled high-level production of a variety of antibodies in different plant organs, like roots/tubers/fruits, leaves and seeds, of a variety of plants, like potato, tobacco, maize, rice, tomato and pea, providing a very wide range of possible plant-based passive immunization therapies. For instance, the production of antibodies in edible tissues would allow for a unique, convenient, needle-less, oral passive immunization at the gastric mucosal surface. The technological advances, together with the innate capacity of plant tissues to assemble complex antibodies, will enable carving a niche in the antibody market. This non-exhaustive review aims to shed light on the role of plants as a flexible expression system for passive immunotherapy, which we envisage to progress alongside the conventional production platforms to manufacture specialized antibodies.

show abstract

“…A number of transgene expression systems are available, some designed to restrict expression to the grain, but others allowing ubiquitous expression (for review, see Hensel et al, 2011). The purification of heterologous products can be a costly process, although in some situations this step is not needed; a good example is provided by the feeding to poultry of transgenic pea expressing an scFv antibody directed against the Eimeria parasite (Zimmermann et al, 2009). In dicotyledonous species such as Nicotiana benthamiana, pharmaceutical proteins have been produced primarily using virus-based magnICON system (ICON Genetics, Germany) in combination with agroinfiltration of the leaf: this approach has been exploited by Bayer Innovation GmbH to develop a patient-specific tumour-vaccine against non-Hodgkin's lymphoma (NHL) which is at present in the clinical phase of testing (Bayer Innovation GmbH, Germany).…”

Section: Introductionmentioning

confidence: 99%

Genetic Transformation of Triticeae Cereals for Molecular Farming

Hensel¹

2011

Genetic Transformation

View full text Add to dashboard Cite

Antibody expressing pea seeds as fodder for prevention of gastrointestinal parasitic infections in chickens

Cited by 56 publications

References 63 publications

Manufacturing antibodies in the plant cell

Manufacturing antibodies in the plant cell

Role of plant expression systems in antibody production for passive immunization

Genetic Transformation of Triticeae Cereals for Molecular Farming

Contact Info

Product

Resources

About